An article in the Fall issue of Wayne Magazine, a North Jersey Media publication, features The Life Raft Group, bringing awareness to the community about our mission to cure GIST, and to support those living [...]
Patient adPatient advocates have gained a new level of confidence thanks to the efforts of 21st Century Cures.
The Life Raft Group, in partnership with the National Institutes of Health, is pleased to announce that applications are currently being accepted for the second meeting of the NIH-LRG Virtual GIST Tumor Board.
Patient advocacy is a vital component in assuring that roadblocks to optimal treatment do not prevent cancer patients from obtaining the help they deserve. Recently, a group from Parent Project Muscular Dystrophy presented the FDA [...]
Marshall Summar, MD to testify on behalf of NORD at 21st Century Cures Hearing in Washington, D. C. on Friday, July 11 at 9 AM ET.
Alianza GIST members from Argentina, Bolivia, Brazil, Colombia, Chile, Cuba, Venezuela, Guatemala, Mexico, and Spain joined representatives from the Life Raft Group in Zurich, Switzerland from May 14 to 17. The major focus of the meeting was to develop a new methodology in order to move towards Alianza GIST autonomy.
With the beautiful mountains of Switzerland and Lake Zurich in the background, 44 GIST Patient representatives from 28 countries and 32 patient groups/organizations convened in Zurich for the New Horizons GIST meeting from May 14-17, 2014.
The 12th Pediatric and Wildtype GIST Clinic was held May 21 to 23, 2014 at the National Institutes of Health in Bethesda, Maryland. Coordinated by Dr. Sosipatros Boikos, and based out of the NIH Pediatric Oncology Department under the direction of Dr. Lee Helman, the Clinic is collaboration between clinicians and researchers to collect data, investigate and develop treatment for GIST patients who do not have either c-KIT or PDGFRA mutation.
The future of cancer treatment relies on patient enrollment in clinical trials. In a recent Chicago Tribune article, a patient story is highlighted to illustrate the important role clinical trials play in cancer treatment, not only in [...]
The 2014 Zurich Declaration Principles for the transition to “Generic Drugs” for GIST (Gastrointestinal Stromal Tumors) Background and Purpose: GIST (Gastrointestinal Stromal Tumor) is a rare sarcoma, with an annual incidence of about 15 persons [...]
